• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者中肌肉减少症的预后价值：一项系统评价和荟萃分析

Prognostic Value of Sarcopenia in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A Systematic Review and Meta-Analysis.

作者信息

Xu Xin-Tian, He Dong-Liang, Tian Meng-Xing, Wu Hui-Jing, Jin Xin

机构信息

Department of Pharmacy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Department of Nutrition, Hengyang Central Hospital, Hengyang, China.

出版信息

Front Nutr. 2022 Feb 25;9:816883. doi: 10.3389/fnut.2022.816883. eCollection 2022.

DOI:10.3389/fnut.2022.816883
PMID:35284466
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8914205/
Abstract

OBJECTIVE

Several studies have reported conflicting results regarding the association between sarcopenia and outcomes in patients with diffuse large B-cell lymphoma (DLBCL). This meta-analysis aimed to evaluate the prognostic value of sarcopenia in patients with DLBCL.

METHODS

PubMed, Embase, and Cochrane Library databases were searched to identify trials exploring the association between sarcopenia and prognosis in patients with DLBCL treated with chemotherapy. A meta-analysis of overall survival (OS), progression-free survival (PFS), treatment completion, and rate of complete response (CR) was performed.

RESULTS

Twelve studies that involved 2,324 patients with DLBCL were included. Sarcopenia was associated with poor OS and PFS in patients with DLBCL, even after adjusting for confounders. Patients with sarcopenia had lower rates of CR and treatment completion than patients without sarcopenia.

CONCLUSIONS

Sarcopenia is a negative predictor of prognosis in patients with DLBCL. Additional and prospective studies investigating the diagnostic criteria for sarcopenia are warranted.

摘要

目的

多项研究报告了关于肌少症与弥漫性大B细胞淋巴瘤（DLBCL）患者预后之间关联的相互矛盾的结果。本荟萃分析旨在评估肌少症在DLBCL患者中的预后价值。

方法

检索PubMed、Embase和Cochrane图书馆数据库，以识别探索肌少症与接受化疗的DLBCL患者预后之间关联的试验。对总生存期（OS）、无进展生存期（PFS）、治疗完成情况和完全缓解率（CR）进行荟萃分析。

结果

纳入了12项涉及2324例DLBCL患者的研究。即使在对混杂因素进行调整后，肌少症仍与DLBCL患者较差的OS和PFS相关。与无肌少症的患者相比，有肌少症的患者CR率和治疗完成率更低。

结论

肌少症是DLBCL患者预后的负面预测因素。有必要开展更多前瞻性研究来调查肌少症的诊断标准。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/b501879426bb/fnut-09-816883-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/33b9348d040d/fnut-09-816883-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/d81c30c9c07c/fnut-09-816883-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/462497490f11/fnut-09-816883-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/b97816cef25d/fnut-09-816883-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/ddcd5663b4df/fnut-09-816883-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/b501879426bb/fnut-09-816883-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/33b9348d040d/fnut-09-816883-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/d81c30c9c07c/fnut-09-816883-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/462497490f11/fnut-09-816883-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/b97816cef25d/fnut-09-816883-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/ddcd5663b4df/fnut-09-816883-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/8914205/b501879426bb/fnut-09-816883-g0006.jpg

相似文献

1
Prognostic Value of Sarcopenia in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A Systematic Review and Meta-Analysis.R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者中肌肉减少症的预后价值：一项系统评价和荟萃分析
Front Nutr. 2022 Feb 25;9:816883. doi: 10.3389/fnut.2022.816883. eCollection 2022.
2
Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗弥漫性大 B 细胞淋巴瘤患者中肌肉减少症的预后影响。
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):567-576. doi: 10.1002/jcsm.12115. Epub 2016 Apr 12.
3
Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.基于老年营养风险指数和肌肉减少症的弥漫性大 B 细胞淋巴瘤患者的预后模型。
BMC Cancer. 2020 May 18;20(1):439. doi: 10.1186/s12885-020-06921-2.
4
Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.弥漫大 B 细胞淋巴瘤患者接受 R-CHOP 样或 CHOP 样方案治疗的临床特征和结局：单中心 8 年经验。
Ann Palliat Med. 2020 Jul;9(4):1442-1452. doi: 10.21037/apm-19-589. Epub 2020 Jul 2.
5
Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy.骨骼肌密度是弥漫性大B细胞淋巴瘤采用利妥昔单抗为基础的化疗免疫治疗疗效的独立预测指标。
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):298-304. doi: 10.1002/jcsm.12161. Epub 2016 Nov 21.
6
[Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].[比较老年弥漫性大B细胞淋巴瘤不同一线治疗的疗效及预后]
Zhonghua Zhong Liu Za Zhi. 2020 Mar 23;42(3):234-241. doi: 10.3760/cma.j.cn112152-20190705-00413.
7
Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者治疗结束时FDG-PET完全缓解状态的预后价值：系统评价与Meta分析
Br J Haematol. 2015 Jul;170(2):185-91. doi: 10.1111/bjh.13420. Epub 2015 Apr 1.
8
[Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].[110例原发性胃肠道弥漫大B细胞淋巴瘤不同分期系统评估及预后分析]
Zhonghua Yi Xue Za Zhi. 2019 Jun 25;99(24):1853-1858. doi: 10.3760/cma.j.issn.0376-2491.2019.24.004.
9
Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy.135例接受R-CHOP或CHOP/类CHOP化疗的弥漫性大B细胞淋巴瘤患者的HBV感染状况临床分析
PLoS One. 2015 Jun 8;10(6):e0129064. doi: 10.1371/journal.pone.0129064. eCollection 2015.
10
Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.内脏脂肪组织对接受一线R-CHOP治疗的弥漫性大B细胞淋巴瘤患者的生存具有预后价值。
Ann Hematol. 2016 Feb;95(3):409-16. doi: 10.1007/s00277-015-2571-0. Epub 2015 Dec 10.

引用本文的文献

1
Prognostic value of baseline body composition parameters from F-FDG PET/CT in angioimmunoblastic T-cell lymphoma patients.F-FDG PET/CT 检查所得基线身体成分参数对血管免疫母细胞性 T 细胞淋巴瘤患者的预后价值
Ann Hematol. 2025 Aug 23. doi: 10.1007/s00277-025-06562-0.
2
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell Lymphoma.身体组成对原发性纵隔大B细胞淋巴瘤患者治疗毒性及预后的影响
Hematol Oncol. 2025 Jul;43(4):e70117. doi: 10.1002/hon.70117.
3
The prognostic value of sarcopenia and sarcopenic obesity in patients with lung cancer receiving immunotherapy: a propensity score matching study.

本文引用的文献

1
Prognostic Impact of Muscle Quantity and Quality and Fat Distribution in Diffuse Large B-Cell Lymphoma Patients.弥漫性大B细胞淋巴瘤患者肌肉数量和质量以及脂肪分布的预后影响
Front Nutr. 2021 May 7;8:620696. doi: 10.3389/fnut.2021.620696. eCollection 2021.
2
Sarcopenia and mortality in cancer: A meta-analysis.癌症中的肌肉减少症与死亡率：一项荟萃分析。
Osteoporos Sarcopenia. 2021 Mar;7(Suppl 1):S28-S33. doi: 10.1016/j.afos.2021.03.002. Epub 2021 Mar 30.
3
Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy.
肌肉减少症和肌肉减少性肥胖在接受免疫治疗的肺癌患者中的预后价值：一项倾向评分匹配研究。
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf114.
4
The prognostic role of Geriatric 8 in patients with cancer: a meta-analysis and systematic review.老年综合评估8项指标对癌症患者的预后作用：一项荟萃分析与系统评价
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf118.
5
Sarcopenia attenuates the efficacy of PEGylated granulocyte colony-stimulating factor in preventing febrile neutropenia.肌肉减少症会削弱聚乙二醇化粒细胞集落刺激因子预防发热性中性粒细胞减少症的疗效。
Support Care Cancer. 2025 Jun 4;33(7):533. doi: 10.1007/s00520-025-09614-3.
6
Effect of Vitamin D and Skeletal Muscle Mass on Prognosis of Patients with Diffuse Large B-Cell Lymphoma.维生素 D 和骨骼肌质量对弥漫性大 B 细胞淋巴瘤患者预后的影响。
Nutrients. 2024 Aug 11;16(16):2653. doi: 10.3390/nu16162653.
7
Implications of Sarcopenia and Glucometabolism Parameters of Muscle Derived From Baseline and End-of-Treatment F-FDG PET/CT in Diffuse Large B-Cell Lymphoma.从基线和治疗结束时 F-FDG PET/CT 中提取的肌肉源性肌肉减少症和糖代谢参数对弥漫性大 B 细胞淋巴瘤的影响。
Korean J Radiol. 2024 Mar;25(3):277-288. doi: 10.3348/kjr.2023.0949.
8
The Role of Geriatric Assessment in the Management of Diffuse Large B-Cell Lymphoma.老年评估在弥漫性大B细胞淋巴瘤管理中的作用
Cancers (Basel). 2023 Dec 14;15(24):5845. doi: 10.3390/cancers15245845.
9
Evaluation of the cachexia index using a bioelectrical impedance analysis in elderly patients with non-Hodgkin's lymphoma: A single-center prospective study.采用生物电阻抗分析法评估非霍奇金淋巴瘤老年患者恶病质指数：一项单中心前瞻性研究。
Ann Hematol. 2024 Mar;103(3):823-831. doi: 10.1007/s00277-023-05548-0. Epub 2023 Nov 27.
10
Geriatric nutritional risk index as a predictor of prognosis in hematologic malignancies: a systematic review and meta-analysis.老年营养风险指数作为血液系统恶性肿瘤预后的预测指标：一项系统评价和荟萃分析
Front Nutr. 2023 Oct 24;10:1274592. doi: 10.3389/fnut.2023.1274592. eCollection 2023.
人体成分分析作为预测弥漫性大 B 细胞淋巴瘤患者接受 R-CHOP 免疫化疗毒性和预后的指标。
Curr Oncol. 2021 Mar 23;28(2):1325-1337. doi: 10.3390/curroncol28020126.
4
Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy.基于利妥昔单抗的化疗免疫治疗的弥漫性大 B 细胞淋巴瘤患者的预后影响：肌肉减少症参数——腰大肌指数。
Leuk Lymphoma. 2021 May;62(5):1098-1106. doi: 10.1080/10428194.2020.1856833. Epub 2020 Dec 10.
5
Sarcopenia predicts overall survival in patients with malignant hematological diseases: A meta-analysis.肌少症预测恶性血液病患者的总生存：一项荟萃分析。
Clin Nutr. 2021 Mar;40(3):1155-1160. doi: 10.1016/j.clnu.2020.07.023. Epub 2020 Jul 23.
6
Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.胰岛素样生长因子-1 受体对弥漫大 B 细胞淋巴瘤发生过程中 Hippo-YAP 信号通路的调控作用
J Hematol Oncol. 2020 Jun 16;13(1):77. doi: 10.1186/s13045-020-00906-1.
7
Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.基于老年营养风险指数和肌肉减少症的弥漫性大 B 细胞淋巴瘤患者的预后模型。
BMC Cancer. 2020 May 18;20(1):439. doi: 10.1186/s12885-020-06921-2.
8
IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells.IGF-1/IGF-1R/FAK/YAP 转导信号促使三阴性乳腺癌 (TNBC) 细胞生长。
Cells. 2020 Apr 18;9(4):1010. doi: 10.3390/cells9041010.
9
Radiologically Defined Sarcopenia Affects Survival in Head and Neck Cancer: A Meta-Analysis.影像学定义的肌肉减少症影响头颈部癌症的生存：一项荟萃分析。
Laryngoscope. 2021 Feb;131(2):333-341. doi: 10.1002/lary.28616. Epub 2020 Mar 27.
10
Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤患者低肌肉量和低肌肉密度的预后影响。
Leuk Lymphoma. 2020 Jul;61(7):1618-1626. doi: 10.1080/10428194.2020.1737686. Epub 2020 Mar 13.